VK5211: Phase II started

Viking began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 0.5, 1 and 2 mg oral VK5211 once daily for 12 weeks in up to 120 patients ages >=65 recovering from hip fracture surger...